Search

Your search keyword '"White, Darrell"' showing total 6 results
Start Over Author "White, Darrell" Journal blood cancer journal
6 results on '"White, Darrell"'

2. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

Author

Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, and Reece, Donna

Published
2023
Full Text
View/download PDF

5. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

Author

Kaufman, Jonathan, Dimopoulos, Meletios, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather, Magen, Hila, Iida, Shinsuke, Kim, Jin, Miles Prince, H, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar, Chari, Ajai, ORourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad, and San-Miguel, Jesus

Subjects
Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chromosome Deletion, Chromosomes, Human, Cytogenetic Analysis, Dexamethasone, Disease-Free Survival, Humans, Lenalidomide, Multiple Myeloma, Recurrence, Survival Rate, Translocation, Genetic
Abstract

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10-5) was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n = 286; Rd, n = 283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; P

Published
2020

6. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Author

Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., and Richardson, Paul G.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results